Analysts Expect Kezar Life Sciences, Inc. (NASDAQ:KZR) Will Announce Earnings of -$0.26 Per Share

Wall Street brokerages expect Kezar Life Sciences, Inc. (NASDAQ:KZR) to announce earnings per share (EPS) of ($0.26) for the current quarter, Zacks reports. Zero analysts have made estimates for Kezar Life Sciences’ earnings, with estimates ranging from ($0.27) to ($0.25). Kezar Life Sciences posted earnings per share of ($0.23) during the same quarter last year, which suggests a negative year over year growth rate of 13%. The company is scheduled to issue its next earnings results on Thursday, November 4th.

According to Zacks, analysts expect that Kezar Life Sciences will report full year earnings of ($1.02) per share for the current year, with EPS estimates ranging from ($1.05) to ($0.95). For the next year, analysts forecast that the firm will post earnings of ($1.27) per share, with EPS estimates ranging from ($1.51) to ($1.09). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Kezar Life Sciences.

Kezar Life Sciences (NASDAQ:KZR) last posted its earnings results on Thursday, August 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.01.

KZR has been the subject of a number of analyst reports. Zacks Investment Research cut shares of Kezar Life Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, September 2nd. Jonestrading began coverage on shares of Kezar Life Sciences in a research note on Tuesday, July 20th. They issued a “buy” rating and a $14.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Kezar Life Sciences in a research note on Monday, August 30th.

A number of large investors have recently added to or reduced their stakes in the stock. Morgan Stanley raised its stake in Kezar Life Sciences by 12,201.9% during the 2nd quarter. Morgan Stanley now owns 1,580,546 shares of the company’s stock valued at $8,583,000 after purchasing an additional 1,567,698 shares during the last quarter. Logos Global Management LP increased its holdings in Kezar Life Sciences by 187.5% in the 2nd quarter. Logos Global Management LP now owns 2,300,000 shares of the company’s stock valued at $12,489,000 after buying an additional 1,500,000 shares during the period. Millennium Management LLC increased its holdings in Kezar Life Sciences by 2.7% in the 2nd quarter. Millennium Management LLC now owns 801,361 shares of the company’s stock valued at $4,351,000 after buying an additional 21,079 shares during the period. New York Life Investments Alternatives increased its holdings in Kezar Life Sciences by 36.8% in the 2nd quarter. New York Life Investments Alternatives now owns 78,868 shares of the company’s stock valued at $428,000 after buying an additional 21,198 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Kezar Life Sciences by 17.9% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 90,011 shares of the company’s stock worth $489,000 after purchasing an additional 13,695 shares during the last quarter. Hedge funds and other institutional investors own 57.36% of the company’s stock.

NASDAQ KZR traded up $0.06 during trading on Thursday, reaching $9.35. The company’s stock had a trading volume of 201,288 shares, compared to its average volume of 254,084. The stock has a market capitalization of $450.60 million, a PE ratio of -9.78 and a beta of 0.41. The business has a 50-day moving average price of $6.59 and a 200-day moving average price of $6.06. Kezar Life Sciences has a 1-year low of $4.34 and a 1-year high of $9.79.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J.

Featured Story: What is the quiet period?

Get a free copy of the Zacks research report on Kezar Life Sciences (KZR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kezar Life Sciences (NASDAQ:KZR)

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.